Last reviewed · How we verify
glargine insulin
Glargine insulin, marketed by Baylor College of Medicine, is a long-acting insulin analog used in the treatment of diabetes, currently holding a significant market position. The key composition patent for glargine insulin is set to expire in 2028, providing a strong competitive advantage until then. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue.
At a glance
| Generic name | glargine insulin |
|---|---|
| Also known as | Lantus insulin, Lantus insulin ™, Sanofi-Aventis, Brazil, Lantus, LANTUS (insulin glargine [rDNA origin] injection |
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glargine insulin CI brief — competitive landscape report
- glargine insulin updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI